2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Classical hematology
1
Conditions
Leukemia, Myeloid, Acute
9
Myelodysplastic Syndromes
3
Squamous Cell Carcinoma of Head and Neck
2
Solid Tumor
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Unresectable Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Sezary Syndrome
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Myeloid Malignancies
1
Mycosis Fungoides
1
Multiple Myeloma
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Brain Neoplasms
1
Anemia, Refractory, with Excess of Blasts
1
Interventions
fludarabine phosphate
60
Cyclophosphamide
60
Busulfan
43
Cyclosporine
41
Mycophenolic Acid
40
Peripheral Blood Stem Cell Transplantation
39
Cytarabine
36
Whole-Body Irradiation
34
Antilymphocyte Serum
29
Filgrastim
26
Tacrolimus
24
Methotrexate
24
fludarabine
23
Cord Blood Stem Cell Transplantation
22
Radiotherapy
21
Melphalan
20
Etoposide
18
Methylprednisolone
15
Azacitidine
14
Granulocyte Colony-Stimulating Factor
13
Idarubicin
12
Daunorubicin
11
Thiotepa
10
sargramostim
8
Cyclosporins
8
Clofarabine
7
Arsenic Trioxide
7
Transplantation
6
Topotecan
6
Mitoxantrone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anemia, Refractory, with Excess of Blasts
×
magrolimab
×
Clear all
NCT05829434
2024-02-12
MAGROLIC
University of Leipzig
Phase 2
Withdrawn